



proposal to make Dovonex Psoriasis Ointment available in Pharmacies Ref: ARM95
<u>Your details</u> Name:
Position (if applicable):
Organisation (if applicable):
Email: 1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?
Yes ✓ No □ Not sure □
Please provide any comments or evidence to support your response:
As a sufferer of psoriasis it seems crazy to have to spend time going, collecting and taking up valuable time at the pharmacy and staff time filling a prescription for a cream that has not real reason to be controlled. As far as I'm aware the only use of this cream is in the control of psoriasis so logically we should be able to buy over the counter. Without as I said being an unnecessary added cost to the NHS system.
2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?
No
Do you have any other comments on the reclassification?
I see nothing but a positive result from reclassification. Assuming that the ointments pricing is affordable.
4. The MHRA may publish consultation responses. Do you want your response to remain confidential?
Yes □ Partially* □ No ✓
*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by 20 April 2017. Contributions received after that date cannot be included in the exercise.